Cell and Gene Therapy CRO Market (3rd Edition): Distribution by Area of Expertise (Cell Therapy and Gene Therapy), Scale of Operation (Clinical, Preclinical and Discovery), Therapeutic Area (Oncological Disorders, Neurological Disorders, Cardiovascular Disorders, Infectious Diseases, Metabolic Disorders, Autoimmune Disorders, Blood Disorders, Rare / Genetic Disorders, Ophthalmological Disorders, and Other disorders), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    September 2022

  • Pages
    330

  • View Count
    17590

Example Insights

Cell-and-Gene-Therapy-CROs-Market1-Context-thumb Cell-and-Gene-Therapy-CROs-Market1-Landscape-thumb Cell-and-Gene-Therapy-CROs-Market1-Distribution-by-Company-thumb Cell-and-Gene-Therapy-CROs-Market1-Clinical-Research-thumb
Cell-and-Gene-Therapy-CROs-Market1-Benchmark-Analysis-thumb Cell-and-Gene-Therapy-CROs-Market1-Partnership-and-Collaborations-thumb Cell-and-Gene-Therapy-CROs-Market1-Mergers-and-Acquisitions-thumb Cell-and-Gene-Therapy-CROs-Market1-Developers-thumb
Cell-and-Gene-Therapy-CROs-Market1-Key-Acquisiton-Targerts-thumb Cell-and-Gene-Therapy-CROs-Market1-Distribution-By-Key-Parameters-thumb Cell-and-Gene-Therapy-CROs-Market1-Distribution-By-Scale-of-Operation-thumb  

Overview

Cell and gene therapy candidates have been demonstrated to have the potential to treat complex and rare diseases, including indications, for which no effective treatment is currently available. In this context, it is important to mention that, in case of cell therapy, human cells are transplanted to repair or replace the damaged cells / tissues, thereby, enabling their treatment through alteration or restoration of certain sets of cells. The cells may originate from the patient (autologous cells) or a donor (allogeneic cells). On the other hand, gene therapy aims to correct the underlying genetic problem to ensure the treatment, as well as prevention of diseases, by replacing, inactivating or introducing genes into cells, either inside or outside of the body. It is worth highlighting that some therapeutic interventions can be considered both cell and gene therapies. The mechanism of action of such therapies usually involves alteration of genes in specific types of cells and then, their insertion into the patient body.

How is the research and development (R&D) activity evolving in the cell and gene therapy industry?

At present, cell and gene therapy industry is one of the fastest growing therapeutic segments, already having contributed to some of the most significant disruptions in the biopharmaceutical domain. Till date, 23 cell and gene therapies have been approved by the Food and Drug Administration (FDA) in the US, while more than 1,000 IND applications have been filed for candidates being evaluated in ongoing clinical studies. This further indicates a remarkable scientific progress and therapeutic promise of these breakthrough drug candidates. 

What is the need for contract research organizations (CROs) in the cell and gene therapy domain?

At present, only a few therapeutic developers have the required technical expertise to carry out in-house clinical research. This can be attributed to the high costs associated with acquiring the necessary infrastructure and capabilities to carry out research. Other key concerns shared by contemporary innovators include limited availability of expertise, high rate of attrition of pipeline drugs / therapies and prolonged development timelines. The aforementioned challenges are believed to be the key factors for driving the outsourcing of research operations to a cell and gene therapy CRO, which claim to be well-aware of the nuances of advanced therapy medicinal products (ATMPs) design and development, as well as cell and gene therapy manufacturing process. 

What are the current opportunities in the cell and gene therapy CRO market?

Due to the upsurge in the research and development related to genetic engineering, there has been a considerable increase in the development of cell and gene therapies. Consequently, there has been a parallel rise in outsourcing of services as more clinical studies are anticipated to start. Specifically, cell and gene therapy companies have made significant investments to support the development / adoption of advanced tools, technologies and platforms, to generate more robust and evidence based clinical data, which is required for gaining the marketing authorizations across different geographies. For instance, in 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain. Further, CROs are believed to play a significant role in the successful approval of these drugs in a highly evolving regulatory environment. Since 2005, over 40 CROs have been established in this domain. It is worth mentioning that cell and gene therapy CROs are bolstering their existing capabilities to offer a wide range of services to their clients. 

What are the recent developments and expected trends in the cell and gene therapy industry?

Presently, more than 3,570 cell and gene therapies are being evaluated across various stages of clinical development for a myriad of disease indications. Given that the demand for cell and gene therapies is indubitably rising, more than 53% mergers and acquisitions have been undertaken by service providers in this market, since 2015. Considering the prevalent trends and projected opportunity associated with the overall cell and gene therapies market, we believe that the cell and gene therapy CRO market is likely to witness a consistent growth, till 2035.

What are the key challenges faced by cell and gene therapy CROs?

One of the key challenges faced by cell and gene therapy CROs is the lack of understanding of the standard operating procedures (SOPs). In addition, various regulatory guidelines render therapies subject to rigorous quality assessments, thereby, making it difficult for firms with limited finances to undertake research initiatives.

What are the key value drivers in the cell and gene therapy market?

A significant rise in healthcare expenditure, R&D spending and booming research have emerged as key value drivers in the cell and gene therapy domain. 

How is the revenue generation potential associated with cell and gene therapy CROs likely to evolve in the coming years?

The cell and gene therapy CROs market is likely to witness a substantial growth in the coming years. It is worth mentioning that, presently in terms of area of expertise, the market is likely to be driven by cell therapies, and this trend is unlikely to change in the foreseen future as well. Further, based on scale of operation, majority of the revenue share is likely to be associated with clinical operations. Specifically, in terms of global regions, the cell and gene therapy market in Asia-Pacific is likely to grow at a relatively faster pace (21%), in the long term. 

Who are the key players engaged in the cell and gene therapy CROs market?

The key players engaged in this domain (which have also been capture in this report) include Altasciences, Allucent, Accelera Charles River Laboratories, Creative Biolabs, CMIC, Evotec, ICON, IQVIA, Labcorp, Medpace, PPD, Precision For Medicine, QPS and Syneos Health.

Scope of the Report

The “Cell and Gene Therapy CROs Market (3rd Edition), 2022-2035: Distribution by Area of Expertise (Cell Therapy and Gene Therapy), Scale of Operation (Clinical, Preclinical and Discovery), Therapeutic Area (Oncological Disorders, Neurological Disorders, Cardiovascular Disorders, Infectious Diseases, Metabolic Disorders, Autoimmune Disorders, Blood Disorders, Rare / Genetic Disorders, Ophthalmological Disorders, and Other disorders), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa)” report features an extensive study of the current market landscape and future potential of the cell and gene therapy CROs market, over the next decade.

The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features: 

  • A detailed overview of the overall market landscape of the cell and gene therapy CROs, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, area of expertise (cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and gene therapy), scale of operation (discovery, preclinical, clinical and commercial) and types of services offered, including [A] preclinical services (bioanalytical services, in-vivo studies, pharmacokinetic and ADME services, preclinical safety studies, toxicology studies and other preclinical services), [B] clinical services (clinical research monitoring, clinical trial management/ clinical project management, data management, safety and pharmacovigilance, and other clinical services), [C] regulatory services (GAP analysis, IND preparation, legal representation and technical dossier submission) and [D] general support services (biostatistics, consulting, post-market assessment, re-imbursement and training).
  • A detailed analysis on the business models that are commonly adopted by the biopharmaceutical industry for outsourcing cell and gene therapies. In addition, it includes information on various factors that drive developers towards outsourcing and key parameters that sponsors must consider while choosing CROs at each phase of drug development process.  
  • Elaborate profiles of key industry players (very large and large companies) based in North America, Europe and Asia-Pacific that offer contract research services for both cell and gene therapies across both preclinical and clinical scales of operation. Each profile features a brief overview of the company, along with details related to its cell and gene therapies-related service portfolio, recent developments, and an informed future outlook.
  • A benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies (in terms of their expertise across various services related to the development of cell and gene therapies). The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to gain a competitive edge in the industry.  
  • An analysis of the recent collaborations within the cell and gene therapy contract research industry, based on several relevant parameters, such as year of partnership, type of partnership, area of expertise, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2015-2022.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2015-2022, based on several parameters, such as year, type of agreement, area of expertise, geographical location of the companies and key value drivers.
  • A detailed acquisition target analysis, taking into consideration historical trend of the activity of players that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • A list of over 310 cell therapy developers that are anticipated to partner with cell therapy CROs. These players have been shortlisted based on several relevant parameters, such as developer strength (based on company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), and availability of other cell therapy capabilities.
  • An in-depth analysis of nearly 235 gene therapy developers that are anticipated to partner with gene therapy CROs and have been shortlisted on the basis of several relevant parameters, such as developer strength (based on company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.
  • An in-depth analysis of completed, ongoing, and planned clinical studies of various cell and gene therapies, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), therapeutic area and key geographical regions.
  • A detailed analysis of the total cost of ownership for large / very large cell and gene therapy contract research organizations. It features an informed estimate of direct and indirect expenses taking into consideration various relevant parameters, over a span of 20 years.
  • A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution highlighting the relative effect of each SWOT parameter on the overall cell and gene therapies research services industry.

One of the key objectives of this report was to evaluate the current opportunity and the future growth potential of the cell and gene therapy CROs market over the coming years. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity across important parameters, such as [A] area of expertise (cell therapy and gene therapy), [B] scale of operation (clinical, preclinical and discovery), [C] therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, infectious diseases, metabolic disorders, autoimmune disorders, blood disorders, rare / genetic disorders, ophthalmological disorders, and other disorders), and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa).  

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION 
3.1. Chapter Overview 
3.2. Overview of Contract Research Organizations (CROs) 
3.2.1. Evolution of CROs 
3.2.2. Modern CROs and Prevalent Outsourcing Trends 
3.3. Type of Services Offered by CROs 
3.4. Classification of CROs 
3.5. Role of CROs in Development of Advanced Therapy Medicinal Products (ATMPs)
3.6. Advantages of Outsourcing Operations to CROs 
3.7. Risks Associated with Outsourcing to CROs 
3.8. Future Perspectives 

4. GUIDE TO OUTSOURCING
4.1. Chapter Overview 
4.2. Outsourcing Cell and Gene Therapy Research  
4.3. Guiding Models of Outsourcing 
4.3.1. Transactional Outsourcing Model 
4.3.2. Performance / Outcome-based Business Model
4.3.3. Staff Augmentation Model
4.3.4. Phase-Dependent Outsourcing Models 
4.4. Selecting an Appropriate Outsourcing Model
4.4.1. Hybrid Approach
4.5. Selecting a CRO Partner
4.5.1 Key Considerations while Outsourcing Cell and Gene Therapy-related Operations
4.6. Role of CROs in Drug Development 
4.6.1. Discovery and Preclinical Research
4.6.2. Early Clinical Research
4.6.3. Clinical Research and Laboratory Services
4.7. Concluding Remarks

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Cell and Gene Therapy CROs: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Scale of Operation
5.3.5. Analysis by Area of Expertise 
5.3.6. Analysis by Number of Preclinical Services
5.3.7. Analysis by Type of Preclinical Service(s) Offered
5.3.8. Analysis by Number of Clinical Services 
5.3.9. Analysis by Type of Clinical Service(s) Offered
5.3.10. Analysis by Type of Regulatory Service(s) Offered
5.3.11. Analysis by Type of General Support Service(s) Offered

6. COMPANY PROFILES
6.1. Chapter Overview 
6.2. Players based in North America
6.2.1. Altasciences
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook

6.2.2. Allucent (Formerly Known as CATO SMS) 
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Recent Developments and Future Outlook

6.2.3. Charles River Laboratories
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Service Portfolio
6.2.3.4. Recent Developments and Future Outlook

6.2.4. Creative Biolabs
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Recent Developments and Future Outlook

6.2.5. IQVIA
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Service Portfolio
6.2.5.4. Recent Developments and Future Outlook

6.2.6. Medpace 
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Service Portfolio
6.2.6.4. Recent Developments and Future Outlook

6.2.7. PPD
6.2.7.1. Company Overview
6.2.7.2. Financial Information
6.2.7.3. Service Portfolio
6.2.7.4. Recent Developments and Future Outlook

6.2.8. Precision for Medicine
6.2.8.1. Company Overview
6.2.8.2. Service Portfolio
6.2.8.3. Recent Developments and Future Outlook

6.2.9. QPS
6.2.9.1. Company Overview
6.2.9.2. Service Portfolio
6.2.9.3. Recent Developments and Future Outlook

6.3. Players based in Europe 
6.3.1. Accelera 
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook

6.3.2. Evotec
6.3.2.1. Company Overview
6.3.2.2. Financial Information
6.3.2.3. Service Portfolio
6.3.2.4. Recent Developments and Future Outlook

6.3.3. ICON
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Recent Developments and Future Outlook

6.3.4. Syneos Health 
6.3.4.1. Company Overview
6.3.4.2. Financial Information
6.3.4.3. Service Portfolio
6.3.4.4. Recent Developments and Future Outlook

6.4. Players based in Asia-Pacific
6.4.1.1. CMIC Group
6.4.1.2. Company Overview
6.4.1.3. Financial Information
6.4.1.4. Service Portfolio
6.4.1.5. Recent Developments and Future Outlook

6.4.2. Labcorp
6.4.2.1. Company Overview
6.4.2.2. Financial Information
6.4.2.3. Service Portfolio
6.4.2.4. Recent Developments and Future Outlook

7. COMPETITIVE BENCHMARKING
7.1. Chapter Overview
7.2. Assumptions and Key Methodology
7.3. Competitive Benchmarking by Region
7.3.1. Competitive Benchmarking: Small Players based in North America (Peer Group I)
7.3.2. Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
7.3.3. Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
7.3.4. Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
7.3.5. Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
7.3.6. Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
7.3.7. Competitive Benchmarking: Small, Mid-sized, Large and Very Large Players based in Asia-Pacific and RoW (Peer Group VII)
7.4. Concluding Remarks

8. PARTNERSHIPS AND COLLABORATIONS 
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cell and Gene Therapy CROs: Partnerships and Collaborations 
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Partnership and Company Size
8.3.5. Analysis by Area of Expertise
8.3.6. Analysis by Year of Partnership and Area of Expertise
8.3.7. Analysis by Type of Partnership and Area of Expertise
8.3.8. Most Active Players: Analysis by Number of Partnerships
8.3.9. Analysis by Region
8.3.9.1. Intracontinental and Intercontinental Deals
8.3.9.2. Local and International Deals

9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models
9.3. Cell and Gene Therapy CROs: Mergers and Acquisitions
9.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
9.3.2. Analysis by Type of Agreement
9.3.3. Analysis by Region
9.3.3.1. Mergers and Acquisitions: Continent-wise Distribution
9.3.3.2. Mergers and Acquisitions: Country-wise Distribution
9.3.4. Most Active Acquirers: Analysis by Number of Acquisitions
9.3.5. Analysis by Key Value Drivers
9.3.6. Analysis by Year of Acquisition and Key Value Drivers
9.3.7. Key Acquisitions: Deal Multiples

10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scoring Criteria and Key Assumptions
10.3. Scope and Methodology
10.4. Potential Strategic Acquisition Targets Amongst Small Players
10.5. Potential Strategic Acquisition Targets Amongst Mid-sized Players

11. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CROs
11.1. Chapter Overview
11.2. Scoring Criteria and Key Assumptions
11.3. Scope and Methodology
11.4. Key Potential Strategic Partners for Cell Therapy CROs
11.4.1. Likely Partner Opportunities for Dendritic Cell Therapy CROs
11.4.2. Likely Partner Opportunities for NK Cell Therapy CROs
11.4.3. Likely Partner Opportunities for Stem Cell Therapy CROs
11.4.4. Likely Partner Opportunities for T-Cell Therapy CROs

12. LIKELY PARTNER ANALYSIS FOR GENE THERAPY CROs
12.1. Chapter Overview
12.2. Scoring Criteria and Key Assumptions
12.3. Scope and Methodology
12.4. Key Potential Strategic Partners for Gene Therapy CROs 
12.4.1. Likely Partner Opportunities in North America
12.4.2. Likely Partner Opportunities in Europe
12.4.3. Likely Partner Opportunities in Asia-Pacific and RoW

13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Cell Therapies: Analysis by Number of Clinical Trials
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Status
13.3.3. Analysis by Trial Phase
13.3.4. Analysis by Therapeutic Area
13.3.5. Analysis by Type of Sponsor
13.3.6. Analysis by Geography
13.3.7. Analysis by Trial Registration Year and Geography
13.3.8. Analysis by Trial Status and Geography
13.3.9. Analysis by Trial Phase and Geography
13.4. Cell Therapies: Analysis by Enrolled Patient Population
13.4.1. Analysis by Trial Registration Year
13.4.2. Analysis by Trial Status
13.4.3. Analysis by Trial Phase
13.4.4. Analysis by Location of Trial Site
13.4.5. Analysis by Trial Status and Location of Trial Site
13.4.6. Analysis by Trial Status, Trial Phase and Location of Trial Site
13.5. Gene Therapies: Analysis by Number of Clinical Trials
13.5.1. Analysis by Trial Registration Year
13.5.2. Analysis by Trial Status
13.5.3. Analysis by Trial Phase
13.5.4. Analysis by Therapeutic Area
13.5.5. Analysis by Type of Sponsor
13.5.6. Analysis by Location of Trial Site
13.5.7. Analysis by Geography
13.5.8. Analysis by Trial Registration Year and Geography
13.5.9. Analysis by Trial Status and Geography
13.5.10. Analysis by Trial Status, Trial Phase and Geography
13.5.11. Analysis by Therapeutic Area and Geography
13.6. Gene Therapies: Analysis by Enrolled Patient Population
13.6.1. Analysis by Trial Registration Year
13.6.2. Analysis by Trial Status
13.6.3. Analysis by Trial Phase
13.6.4. Analysis by Therapeutic Area
13.6.5. Analysis by Location of Trial Site
13.6.6. Analysis by Trial Status and Location of Trial Site
13.6.7. Analysis by Trial Status, Trial Phase and Location of Trial Site
13.6.8. Analysis by Therapeutic Area and Location of Trial Site

14. TOTAL COST OF OWNERSHIP FOR CELL AND GENE THERAPY CONTRACT RESEARCH ORGANIZATIONS
14.1 Chapter Overview
14.2. Key Parameters
14.3. Assumptions and Methodology
14.4. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2022-2042
14.4.1. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by CAPEX and OPEX, 2023-2042
14.4.2. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by CAPEX, 2023-2042
14.4.3. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by OPEX, 2023-2042

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology 

15.3. Global Cell and Gene Therapy CROs Market, 2022-2035
15.3.1. Cell and Gene Therapy CROs Market: Analysis by Area of Expertise
15.3.1.1. Cell Therapy CROs Market, 2022-2035
15.3.1.2. Gene Therapy CROs Market, 2022-2035

15.3.2. Cell and Gene Therapy CROs Market: Analysis by Scale of Operation
15.3.2.1. Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035
15.3.2.2. Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035
15.3.2.3. Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035

15.3.3. Cell and Gene Therapy CROs Market: Analysis by Therapeutic Area, 2022-2035
15.3.3.1. Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035
15.3.3.2. Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035
15.3.3.3. Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035
15.3.3.4. Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035
15.3.3.5. Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035
15.3.3.6. Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035
15.3.3.7. Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035
15.3.3.8. Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035
15.3.3.9. Cell and Gene Therapy CROs Market for Ophthalmological Disorders, 2022-2035
15.3.3.10. Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035

15.3.4. Cell and Gene Therapy CROs Market: Analysis by Geography, 2022-2035
15.3.4.1. Cell and Gene Therapy CROs Market in North America, 2022-2035
15.3.4.2. Cell and Gene Therapy CROs Market in Europe, 2022-2035
15.3.4.3. Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035
15.3.4.4. Cell and Gene Therapy CROs Market in Latin America, 2022-2035
15.3.4.5. Cell and Gene Therapy CROs Market in MENA, 2022-2035

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors

17. CONCLUSION
17.1. Chapter Overview

18. INTERVIEW AND SURVEY TRANSCRIPTS
18.1. Chapter Overview
18.2. CATO SMS
18.2.1. Company Snapshot
18.2.2. Survey Transcript: Jessica Bliven, Director, Marketing and Sales

18.3. Changhai Hospital, Second Military Medical University
18.3.1. University Snapshot
18.3.2. Survey Transcript: Xian-Bao Zhan, Professor of Medicine, Director,Department of Oncology

18.4. University of Colorado
18.4.1. University Snapshot
18.4.2. Survey Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

19. APPENDIX I: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Mergers and Acquisitions
Figure 2.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Stages of the Drug Development Process
Figure 3.2 Services Offered by CROs
Figure 3.3 Advantages of Outsourcing Operations to CROs
Figure 3.4 Risks Associated with Outsourcing Operations to CROs
Figure 3.5 Classification of ATMPs
Figure 3.6 Types of Cells Incorporated in Cell Therapy Medicinal Products (CTMPs)
Figure 4.1 Guiding Models of Outsourcing
Figure 4.2 Key Characteristics of Transactional Outsourcing Model
Figure 4.3 Key Characteristics of Performance / Outcome-based Business Model
Figure 4.4 Key Considerations while Selecting a CRO Partner
Figure 4.5 Role of CROs across Different Phases of Drug Development
Figure 5.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment
Figure 5.2 Cell and Gene Therapy CROs: Distribution by Company Size
Figure 5.3 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Region-wise)
Figure 5.4 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Country-wise)
Figure 5.5 Cell and Gene Therapy CROs: Distribution by Year of Establishment, Company Size, and Location of Headquarters
Figure 5.6 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Figure 5.7 Cell and Gene Therapy CROs: Distribution by Area of Expertise
Figure 5.8 Cell and Gene Therapy CROs: Distribution by Scale of Operation and Area of Expertise
Figure 5.9 Cell and Gene Therapy CROs: Distribution by Type of Cell Therapy
Figure 5.10 Cell and Gene Therapy CROs: Distribution by Number of Preclinical Services
Figure 5.11 Cell and Gene Therapy CROs: Distribution by Type of Preclinical Service(s) Offered
Figure 5.12 Cell and Gene Therapy CROs: Distribution by Number of Clinical Services
Figure 5.13 Cell and Gene Therapy CROs: Distribution by Type of Clinical Service(s) Offered
Figure 5.14 Cell and Gene Therapy CROs: Distribution by Type of Regulatory Service(s) Offered
Figure 5.15 Cell and Gene Therapy CROs: Distribution by Type of General Service(s) Offered
Figure 6.1 Altasciences: Service Portfolio
Figure 6.2 Allucent (Formerly known as CATO SMS): Service Portfolio
Figure 6.3 Charles River Laboratories: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Figure 6.4 Charles River Laboratories: Service Portfolio
Figure 6.5 Creative Biolabs: Service Portfolio for CAR-T Therapy Development
Figure 6.6 Creative Biolabs: Service Portfolio for TCR Therapy Development
Figure 6.7 IQVIA: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Figure 6.8 IQVIA: Service Portfolio
Figure 6.9 Medpace: Annual Revenues, FY 2017-Q1 2022 (USD Million)
Figure 6.10 Medpace: Service Portfolio
Figure 6.11 Medpace: Regulatory Affair Capabilities
Figure 6.12 PPD: Annual Revenues, FY 2017-9M 2021 (USD Billion)
Figure 6.13 PPD: Service Portfolio
Figure 6.14 Precision for Medicine: Service Portfolio
Figure 6.15 QPS: Service Portfolio
Figure 6.16 Accelera: Service Portfolio
Figure 6.17 Evotec: Annual Revenues, FY 2017-Q1 2022 (EUR Million)
Figure 6.18 Evotec: Service Portfolio
Figure 6.19 ICON: Service Portfolio
Figure 6.20 Syneos Health: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Figure 6.21 Syneos Health: Service Portfolio
Figure 6.22 CMIC Group: Annual Revenues, 2017-H1 2022 (JPY Billion)
Figure 6.23 CMIC Group: Service Portfolio
Figure 6.24 Labcorp: Annual Revenues, FY 2017- Q1 2022 (USD Billion)
Figure 6.25 Labcorp: Service Portfolio
Figure 7.1 Benchmark Analysis: Distribution by Location of Headquarters and Company Size
Figure 7.2 Competitive Benchmarking: Small Players based in North America (Peer Group I)
Figure 7.3 Competitive Benchmarking: Mid-Sized Players based in North America (Peer Group II)
Figure 7.4 Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
Figure 7.5 Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
Figure 7.6 Competitive Benchmarking: Mid-Sized Players based in Europe (Peer Group V)
Figure 7.7 Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
Figure 7.8 Competitive Benchmarking: Small, Mid-sized, Large and Very Large Players based in Asia-Pacific and RoW (Peer Group VII)
Figure 7.9 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 8.5 Partnerships and Collaborations: Distribution by Area of Expertise
Figure 8.6 Partnerships and Collaborations: Distribution by Year of Partnership and Area of Expertise
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partnership and Area of Expertise
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Figure 8.10 Partnerships and Collaborations: Local and International Deals
Figure 9.1 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2015-2022
Figure 9.2 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 9.3 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Figure 9.4 Mergers and Acquisitions: Distribution by Region (Country-wise)
Figure 9.5 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 9.6 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 9.7 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 9.8 Mergers and Acquisitions: Distribution by Deal Multiples Based on Revenues
Figure 13.1 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Figure 13.2 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Figure 13.3 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Figure 13.4 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area
Figure 13.5 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor
Figure 13.6 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Number of Registered Trials
Figure 13.7 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Registration Year
Figure 13.8 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Status
Figure 13.9 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Phase
Figure 13.10 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 13.11 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Status
Figure 13.12 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Phase
Figure 13.13 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population
Figure 13.14 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status
Figure 13.15 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population by Trial Phase
Figure 13.16 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Figure 13.17 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Figure 13.18 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Figure 13.19 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area
Figure 13.20 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor
Figure 13.21 Clinical Trial Analysis for Gene Therapies: Distribution by Location of Trial Site
Figure 13.22 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Number of Registered Trials
Figure 13.23 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Registration Year
Figure 13.24 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Status
Figure 13.25 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Status and Trial Phase
Figure 13.26 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Therapeutic Area
Figure 13.27 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 13.28 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Status
Figure 13.29 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Phase
Figure 13.30 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Therapeutic Area
Figure 13.31 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population
Figure 13.32 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status
Figure 13.33 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status and Trial Phase
Figure 13.34 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Therapeutic Area
Figure 14.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 14.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 14.3 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2022-2042 (USD Million)
Figure 14.4 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Distribution by CAPEX and OPEX, 2023 and 2042 (USD Million)
Figure 14.5 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2023: Distribution by CAPEX (USD Million)
Figure 14.6 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2023-2042: Distribution by OPEX (USD Million)
Figure 15.1 Global Cell and Gene Therapy CROs Market, 2022-2035 (USD Million)
Figure 15.2 Cell and Gene Therapy CROs Market: Distribution by Area of Expertise
Figure 15.3 Cell Therapy CROs Market, 2022-2035 (USD Million)
Figure 15.4 Gene Therapy CROs Market, 2022-2035 (USD Million)
Figure 15.5 Cell and Gene Therapy CROs Market: Distribution by Scale of Operation
Figure 15.6 Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035 (USD Million)
Figure 15.7 Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035 (USD Million)
Figure 15.8 Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035 (USD Million)
Figure 15.9 Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area
Figure 15.10 Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035 (USD Million)
Figure 15.11 Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035 (USD Million)
Figure 15.12 Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035 (USD Million)
Figure 15.13 Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035 (USD Million)
Figure 15.14 Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035 (USD Million)
Figure 15.15 Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035 (USD Million)
Figure 15.16 Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035 (USD Million)
Figure 15.17 Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035 (USD Million)
Figure 15.18 Cell and Gene Therapy CROs Market for Ophthalmological Disorders, 2022-2035 (USD Million)
Figure 15.19 Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035 (USD Million)
Figure 15.20 Cell and Gene Therapy CROs Market: Distribution by Geography, 2022 and 2035
Figure 15.21 Cell and Gene Therapy CROs Market in North America, 2022-2035 (USD Million)
Figure 15.22 Cell and Gene Therapy CROs Market in Europe, 2022-2035 (USD Million)
Figure 15.23 Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035 (USD Million)
Figure 15.24 Cell and Gene Therapy CROs Market in Latin America, 2022-2035 (USD Million)
Figure 15.25 Cell and Gene Therapy CROs Market in MENA, 2022-2035 (USD Million)
Figure 16.1 Cell and Gene Therapy CROs SWOT Analysis: Overview
Figure 17.1 Concluding Remarks: Overall Market Landscape
Figure 17.2 Concluding Remarks: Partnerships and Collaborations
Figure 17.3 Concluding Remarks: Mergers and Acquisitions
Figure 17.4 Concluding Remarks: Clinical Trial Analysis
Figure 17.5 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 List of Approved ATMP Products
Table 4.1 Attributes of Transactional Outsourcing-based Business Model
Table 5.1 List of Cell and Gene Therapy CROs
Table 5.2 Cell and Gene Therapy CROs: Information on Type of Preclinical Service(s) Offered
Table 5.3 Cell and Gene Therapy CROs: Information on Type of Clinical Service(s) Offered
Table 5.4 Cell and Gene Therapy CROs: Information on Type of Regulatory Service(s) Offered
Table 5.5 Cell and Gene Therapy CROs: Information on Type of General Service(s) Offered
Table 6.1 Altasciences: Company Overview
Table 6.2 Altasciences: Recent Developments and Future Outlook
Table 6.3 Allucent (Formerly known as CATO SMS): Company Overview
Table 6.4 Allucent (Formally Known as CATO SMS): Recent Developments and Future Outlook
Table 6.5 Charles River Laboratories: Company Overview
Table 6.6 Charles River Laboratories: Recent Developments and Future Outlook
Table 6.7 Creative Biolabs: Company Overview
Table 6.8 IQVIA: Company Overview
Table 6.9 Medpace: Company Overview
Table 6.10 PPD: Company Overview
Table 6.11 PPD: Recent Developments and Future Outlook
Table 6.12 Precision for Medicine: Company Overview
Table 6.13 Precision for Medicine: Recent Developments and Future Outlook
Table 6.14 QPS: Company Overview
Table 6.15 Accelera: Company Overview
Table 6.16 Evotec: Company Overview
Table 6.17 ICON: Company Overview
Table 6.18 ICON: Recent Developments and Future Outlook
Table 6.19 Syneos Health: Company Overview
Table 6.20 Syneos Health: Recent Developments and Future Outlook
Table 6.21 CMIC Group: Company Overview
Table 6.22 CMIC Group: Recent Developments and Future Outlook
Table 6.23 Labcorp: Company Overview
Table 6.24 Labcorp: Recent Developments and Future Outlook
Table 7.1 Benchmark Analysis: Peer Groups
Table 8.1 Cell and Gene Therapy CROs: List of Partnerships and Collaborations, 2015-2022
Table 9.1 Cell and Gene Therapy CROs: List of Mergers and Acquisitions, 2015-2022
Table 9.2 Cell and Gene Therapy CROs Mergers and Acquisitions: Information on Key Value Drivers and Area of Expertise, 2015-2022
Table 9.3 Mergers and Acquisitions: Information on Deal Multiples, 2015-2022
Table 10.1 Potential Strategic Acquisition Targets Amongst Small Players
Table 10.2 Potential Strategic Acquisition Targets Amongst Mid-sized Players
Table 11.1 Likely Partners for Dendritic Cell Therapy CROs
Table 11.2 Likely Partners for NK Cell Therapy CROs
Table 11.3 Likely Partners for Stem Cell Therapy CROs
Table 11.4 Likely Partners for T-Cell Therapy CROs
Table 12.1 Likely Partner Opportunities in North America
Table 12.2 Likely Partner Opportunities in Europe
Table 12.3 Likely Partner Opportunities in Asia-Pacific and RoW
Table 13.1 Clinical Trial Analysis: Emerging Molecules
Table 13.2 Clinical Trial Analysis: Most Important Trials
Table 19.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment
Table 19.2 Cell and Gene Therapy CROs: Distribution by Company Size
Table 19.3 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Region-wise)
Table 19.4 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Country-wise)
Table 19.5 Cell and Gene Therapy CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 19.6 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Table 19.7 Cell and Gene Therapy CROs: Distribution by Area of Expertise
Table 19.8 Cell and Gene Therapy CROs: Distribution by Scale of Operation and Area of Expertise
Table 19.9 Cell and Gene Therapy CROs: Distribution by Type of Cell Therapy
Table 19.10 Cell and Gene Therapy CROs: Distribution by Number of Preclinical Services
Table 19.11 Cell and Gene Therapy CROs: Distribution by Type of Preclinical Service(s) Offered
Table 19.12 Cell and Gene Therapy CROs: Distribution by Number of Clinical Services
Table 19.13 Cell and Gene Therapy CROs: Distribution by Type of Clinical Service(s) Offered
Table 19.14 Cell and Gene Therapy CROs: Distribution by Type of Regulatory Service(s) Offered
Table 19.15 Cell and Gene Therapy CROs: Distribution by Type of General Service(s) Offered
Table 19.16 Charles River Laboratories: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Table 19.17 IQVIA: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Table 19.18 Medpace: Annual Revenues, FY 2017-Q1 2022 (USD Million)
Table 19.19 PPD: Annual Revenues, FY 2017-9M 2021 (USD Billion)
Table 19.20 Evotec: Annual Revenues, FY 2017-Q1 2022 (EUR Million)
Table 19.21 Syneos Health: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Table 19.22 CMIC Group: Annual Revenues, 2017-H1 2022 (JPY Billion)
Table 19.23 Labcorp: Annual Revenues, FY 2017- Q1 2022 (USD Billion)
Table 19.24 Benchmark Analysis: Distribution by Location of Headquarters and Company Size
Table 19.25 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Table 19.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.27 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 19.28 Partnerships and Collaborations: Distribution by Area of Expertise
Table 19.29 Partnerships and Collaborations: Distribution by Year of Partnership and Area of Expertise
Table 19.30 Most Active Players: Distribution by Number of Partnerships
Table 19.31 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Table 19.32 Partnerships and Collaborations: Local and International Deals
Table 19.33 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2015-2022
Table 19.34 Mergers and Acquisitions: Distribution by Type of Agreement
Table 19.35 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Table 19.36 Mergers and Acquisitions: Distribution by Region (Country-wise)
Table 19.37 Most Active Acquirers: Distribution by Number of Acquisitions
Table 19.38 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 19.39 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 19.40 Mergers and Acquisitions: Deal Multiples Based on Revenues
Table 19.41 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Table 19.42 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Table 19.43 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Table 19.44 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area
Table 19.45 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor
Table 19.46 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Number of Registered Trials
Table 19.47 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Registration Year
Table 19.48 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Status
Table 19.49 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Phase
Table 19.50 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
Table 19.51 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Status
Table 19.52 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Phase
Table 19.53 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population
Table 19.54 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status
Table 19.55 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population by Trial Phase
Table 19.56 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Table 19.57 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Table 19.58 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Table 19.59 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area
Table 19.60 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor
Table 19.61 Clinical Trial Analysis for Gene Therapies: Distribution by Location of Trial Site
Table 19.62 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Number of Registered Trials
Table 19.63 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Registration Year
Table 19.64 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Status
Table 19.65 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Status and Trial Phase
Table 19.66 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Therapeutic Area
Table 19.67 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
Table 19.68 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Status
Table 19.69 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Phase
Table 19.70 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Therapeutic Area
Table 19.71 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population
Table 19.72 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status
Table 19.73 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status and Trial Phase
Table 19.74 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Therapeutic Area
Table 19.75 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2022-2042 (USD Million)
Table 19.76 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Distribution by CAPEX and OPEX, 2023 and 2042 (USD Million)
Table 19.77 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2023: Distribution by CAPEX (USD Million)
Table 19.78 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2023-2042: Distribution by OPEX (USD Million)
Table 19.79 Global Cell and Gene Therapy CROs Market 2022-2035 (USD Million)
Table 19.80 Cell and Gene Therapy CROs Market: Distribution by Area of Expertise
Table 19.81 Cell Therapy CROs Market, 2022-2035 (USD Million)
Table 19.82 Gene Therapy CROs Market, 2022-2035 (USD Million)
Table 19.83 Cell and Gene Therapy CROs Market: Distribution by Scale of Operation
Table 19.84 Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035 (USD Million)
Table 19.85 Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035 (USD Million)
Table 19.86 Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035 (USD Million)
Table 19.87 Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area
Table 19.88 Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035 (USD Million)
Table 19.89 Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035 (USD Million)
Table 19.90 Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035 (USD Million)
Table 19.91 Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035 (USD Million)
Table 19.92 Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035 (USD Million)
Table 19.93 Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035 (USD Million)
Table 19.94 Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035 (USD Million)
Table 19.95 Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035 (USD Million)
Table 19.96 Cell and Gene Therapy CROs Market for Ophthalmological Disorders, 2022-2035 (USD Million)
Table 19.97 Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035
Table 19.98 Cell and Gene Therapy CROs Market: Distribution by Geography, 2022 and 2035 (USD Million)
Table 19.99 Cell and Gene Therapy CROs Market in North America, 2022-2035 (USD Million)
Table 19.100 Cell and Gene Therapy CROs Market in Europe, 2022-2035 (USD Million)
Table 19.101 Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035 (USD Million)
Table 19.102 Cell and Gene Therapy CROs Market in Latin America, 2022-2035 (USD Million)
Table 19.103 Cell and Gene Therapy CROs Market in MENA, 2022-2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

  1. 3P Biopharmaceuticals
  2. 4Clinics
  3. 4D Molecular Therapeutics
  4. AAVantgarde Bio
  5. AavantiBio
  6. aaVective
  7. AaviGen
  8. AAVogen
  9. Abeona Therapeutics
  10. Absorption Systems Systems (Acquired by Pharmaron) 
  11. Accelera
  12. AccelLAB
  13. Accelovance
  14. Accord Research
  15. Acer Therapeutics
  16. Activartis Biotech
  17. Adaptimmune Therapeutics
  18. Adicet Bio
  19. Adrenas Therapeutics
  20. Aduro Biotech
  21. Advanced BioScience Laboratories
  22. Advanced Cell Diagnostics 
  23. Advaxis
  24. Advent Bioservices
  25. Adverum Biotechnologies
  26. Aevitas Therapeutics
  27. Affinia Therapeutics
  28. Agathos Biologics
  29. AGC Biologics
  30. AgenTus Therapeutics
  31. AGINKO Research
  32. AGTC
  33. Akouos
  34. Akron Biotech
  35. Alia Therapeutics
  36. Allele Biotechnology and Pharmaceuticals
  37. Allergan (Acquired by AbbVie)
  38. Allife Medical Science and Technology
  39. Allogene Therapeutics
  40. Allucent (Formerly known as CATO SMS)
  41. Alpha Cognition
  42. AlphaVax
  43. Altasciences
  44. Altheia Science
  45. Altor BioScience
  46. Amarna Therapeutics
  47. Ambulero
  48. American Gene Technologies
  49. Amgen
  50. Amphera
  51. Amulet Capital Partners
  52. Anaeropharma Science
  53. AnGes
  54. Anhui Kedgene Biotechnology
  55. ANI Pharmaceuticals
  56. Anjarium Biosciences
  57. Ankarys Therapeutics 
  58. HebeCell
  59. Anlong Biopharmaceutical
  60. apceth Biopharma
  61. Apellis Pharmaceuticals
  62. Applied StemCell
  63. ARBELE 
  64. Argos Therapeutics
  65. Aruvant Sciences
  66. ASC Therapeutics
  67. Ascendance Biotechnology
  68. Ascidian Therapeutics
  69. Asklepios BioPharmaceutical
  70. Aspa Therapeutics
  71. Aspire Health Science
  72. Astellas Pharma
  73. Asterand Bioscience
  74. Asterias Biotherapeutics
  75. AstraZeneca
  76. Atamyo Therapeutics
  77. Atara Biotherapeutics
  78. Athersys
  79. Atreca
  80. Atsena Therapeutics
  81. Aurigon
  82. Aurora Biopharma
  83. Austrianova
  84. Autolus
  85. Avance Biosciences
  86. Avance Clinical
  87. Avania
  88. AVAX Technologies
  89. AviadoBio
  90. Avrion Therapeutics
  91. AVROBIO
  92. Axovia Therapeutics
  93. Basic Pharma
  94. Baxalta
  95. Baxter
  96. Bayer
  97. Be The Match BioTherapies
  98. Beam Therapeutics
  99. Beijing Biohealthcare Biotechnology
  100. Beijing Doing Biomedical
  101. Beijing Immunochina Medical Science & Technology
  102. Beijing Sanwater Biological Technology
  103. Beijing Tricision Biotherapeutics 
  104. Beike Biotechnology
  105. Belief BioMed
  106. Bellicum Pharmaceuticals
  107. Bio Elpida
  108. BioAccess
  109. BioAgilytix
  110. BioAtla
  111. BioCardia
  112. BioCentriq
  113. Biogen
  114. Bioheng
  115. Bioinova
  116. Biointaxis
  117. BioIVT
  118. BioMarin Pharmaceutical
  119. Biomere
  120. BioNTech
  121. BioRestorative Therapies 
  122. Bio-Techne 
  123. Biotect Services
  124. BioVec Pharma
  125. Bioville
  126. bluebird bio
  127. Bone Therapeutics
  128. Borea Therapeutics
  129. BrainStorm Cell Therapeutics
  130. BridgeBio
  131. Bristol-Myers Squibb
  132. C3i (Center of Excellence for Cellular Therapy)
  133. Caladrius Biosciences
  134. Cambridge Biomedical
  135. Cambridge Gene Therapy
  136. Candel Therapeutics
  137. Capricor Therapeutics
  138. Capsida Biotherapeutics
  139. Captain T Cell
  140. CardioCell
  141. Carina Biotech
  142. CARsgen Therapeutics
  143. Car-T Shanghai Biotech
  144. Cartherics
  145. Castle Creek Biosciences
  146. Catalent Biologics
  147. Catalyst Biosciences
  148. Ce3
  149. Celgene
  150. Celixir
  151. Cell and Gene Therapy Catapult
  152. Cell Biotech
  153. Cell Genesys
  154. Cell Therapies
  155. Cell-Easy
  156. Cellectar Biosciences
  157. Cellectis
  158. Cellero (Acquired by Charles River Laboratories)
  159. Cellex Cell Professionals
  160. CellGenTech
  161. Cellin Technologies
  162. Cellmed
  163. CellMP (subsidiary of Emmecell)
  164. CellPraxis
  165. CellProtect Biotechnology
  166. CellProtect Nordic Pharmaceuticals
  167. CellProthera
  168. CellTrans
  169. Cellular Therapeutics
  170. Celonic
  171. Celsion
  172. Celularity
  173. Celyad
  174. CG Oncology
  175. CHA Biolab
  176. Charles River Laboratories
  177. Chengdu MedGenCell
  178. Chiltern
  179. Chimeric Therapeutics
  180. China Regenerative Medicine International
  181. CiMaas
  182. Citoxlab
  183. City of Hope
  184. Clean Cells
  185. Clearside Biomedical
  186. Clinical Network Services (CNS)
  187. Clinscience
  188. Cmed Clinical Services
  189. CMIC
  190. CO.DON
  191. Coave Therapeutics
  192. CODA Biotherapeutics
  193. Code Biotherapeutics
  194. Cogent Biosciences
  195. Cognate BioServices
  196. CoImmune
  197. CombiGene
  198. Comparative Biosciences
  199. Cook MyoSite
  200. Copernicus Therapeutics
  201. Corestem
  202. Covance
  203. CRC Oncology
  204. Creative Biolabs
  205. CRISPR Therapeutics
  206. Crown Bioscience
  207. CSL Behring
  208. CTI Clinical Trial and Consulting Services
  209. Cynvec
  210. Cytopeutics
  211. Cytovac
  212. Daiichi Sankyo
  213. DanDrit Biotech
  214. DCPrime
  215. Decibel Therapeutics
  216. Deep Science Ventures
  217. Delta-Vir
  218. Dendreon
  219. Diamond Pharma Services (acquired by ProPharma)
  220. DiNAQOR
  221. DiscGenics
  222. DNAlite Therapeutics
  223. DNAtrix
  224. Editas Medicine
  225. ElevateBio
  226. Eli Lilly
  227. Emendo Biotherapeutics
  228. Emmes
  229. Encoded Therapeutics
  230. Endocyte
  231. Endsulin
  232. enGene
  233. Enochian BioSciences
  234. Envigo
  235. Epeius Biotechnologies
  236. Ergomed
  237. Eureka Therapeutics
  238. Eutilex
  239. Ever Union Biotechnology 
  240. Evotec
  241. Evox Therapeutics
  242. Excelya
  243. Excision BioTherapeutics
  244. Exegenesis Bio
  245. Experior
  246. Expression Therapeutics
  247. EXUMA Biotech
  248. Eyevensys
  249. Fast-Track Drugs and Biologics
  250. Fate Therapeutics
  251. FerGene (Ferring Pharmaceuticals subsidiary)
  252. Ferrer Internacional
  253. FGK Clinical Research
  254. Fibrocell Technologies
  255. Five Prime Therapeutics
  256. Flash Therapeutics
  257. Flexion Therapeutics
  258. Forge Biologics
  259. Formula Pharmaceuticals
  260. Fortress Biotech
  261. Fosun Kite Biotechnology
  262. Freeline Therapeutics
  263. Froceth
  264. Frontage Laboratories
  265. Gadeta
  266. Gamida Cell
  267. GC Cell (Previously known as Green Cross Cell)
  268. Geistek Pharmaceuticals
  269. GenCure (A subsidiary of BioBridge Global)
  270. Gene Therapy Research Institution
  271. GeneCure Biotechnologies
  272. Genelux
  273. GeneMedicine
  274. Genenta Science
  275. Genentech
  276. GeneOne Life Science
  277. GeneQuine Biotherapeutics
  278. Generation Bio
  279. Genesis Biotechnology
  280. Genespire
  281. Genethon
  282. GeneWerk
  283. Genexine
  284. Genflow Biosciences
  285. GenIbet Biopharmaceuticals
  286. GenoSafe
  287. Genprex
  288. GenSight Biologics
  289. Genzyme
  290. GigaGen 
  291. GlaxoSmithKline
  292. Global Cell Med
  293. Global Center for Medical Innovation
  294. Glycostem Therapeutics
  295. Gradalis
  296. Graphite Bio
  297. Green Cross
  298. Green Cross LabCell
  299. GRI Bio
  300. Gsap
  301. Guangzhou Trinomab Biotech
  302. Gyroscope Therapeutics
  303. Heat Biologics
  304. Hebei Senlang Biotechnology
  305. Helixmith
  306. HemaCare
  307. HemoGenix
  308. Hemostemix
  309. HengRui YuanZheng Bio-Technology
  310. Herantis Pharma
  311. Histocell
  312. Histogenics
  313. Holostem Terapie Avanzate
  314. Homology Medicines
  315. Huida (Shanghai) Biotechnology
  316. Human Stem Cells Institute PJSC
  317. HuMurine Technologies
  318. Hunan Zhaotai Yongren Biotech
  319. iCarTAB BioMed
  320. iCell Gene Therapeutics
  321. ICON
  322. ICRC-Weyer
  323. iECURE
  324. Ikarovec
  325. Ilya Pharma
  326. Imanis Life Sciences
  327. Immatics
  328. Immune Therapeutics
  329. Immunicum
  330. ImmunoCellular Therapeutics
  331. Immunocore
  332. Immunovative Therapies 
  333. Immutep
  334. IMS Health
  335. INC Research
  336. IncoCell Tianjin (A subsidiary of Boyalife)
  337. Incysus
  338. Innovative Cellular Therapeutics
  339. Inovio Pharmaceuticals
  340. inRegen
  341. Intas Pharmaceuticals
  342. Intellia Therapeutics
  343. International Stem Cell Corporation
  344. Intertek Pharmaceutical Services
  345. inVentiv Health
  346. Iovance Biotherapeutics
  347. IPM Biotech
  348. IQVIA
  349. ISTO Technologies
  350. IVERIC bio
  351. Ivy Life Sciences
  352. Jaguar Gene Therapy
  353. Janssen
  354. Janssen Pharmaceuticals
  355. Japan Tissue Engineering
  356. Jeune (A subsidiary of Krystal Biotech)
  357. Juno Therapeutics
  358. JW Biotechnology
  359. JW CreaGene
  360. Kadimastem
  361. Kate Therapeutics
  362. KBI Biopharma
  363. KCR
  364. Kuopio Center for Gene and Cell Therapy 
  365. Kiadis Pharma
  366. Kiromic
  367. Kite Pharma
  368. Klinar CRO
  369. Kodikaz Therapeutic Solutions
  370. Kolon TissueGene
  371. Kriya Therapeutics
  372. Krystal Biotech
  373. Kubota Vision
  374. Kuur Therapeutics
  375. LabCorp
  376. Lacerta Therapeutics
  377. LatinaBA 
  378. Legend Biotech
  379. Lentistem® Biotech
  380. Leucid Bio
  381. LEXEO Therapeutics
  382. Lifecells
  383. Lineage Cell Therapeutics
  384. Linical
  385. Linical Accelovance
  386. Lion TCR
  387. Living Pharma
  388. LogicBio Therapeutics
  389. Lokon Pharma
  390. Longeveron
  391. Longmore 60 Biotech
  392. Lovelace Biomedical
  393. Lumos Pharma
  394. Lyell Immunopharma
  395. Lykan Bioscience
  396. Lysogene
  397. Magenta Therapeutics
  398. Marino Biotechnology
  399. MaxCyte
  400. Medelis
  401. Medeor Therapeutics
  402. Medidee
  403. Medigene
  404. MEDINET
  405. Mediphage Bioceuticals
  406. MEDIPOST
  407. Medpace
  408. MedVax Technologies
  409. MeiraGTx
  410. Merck Serono
  411. Mesoblast
  412. Metagenomi
  413. MetbAxis
  414. MI Bioresearch
  415. Milo Biotechnology
  416. Minaris Regenerative Medicine
  417. Minovia Therapeutics
  418. MolecuVax
  419. Momotaro-Gene
  420. Momotaro-Gene
  421. Moraga Biotechnology
  422. MPI Research
  423. Multimmune
  424. MultiVir
  425. Mustang Bio 
  426. Myosana Therapeutics
  427. KAEDI Biotech
  428. Nanoscope Therapeutics
  429. NantKwest
  430. Navega Therapeutics
  431. Neopharm
  432. NetValue BioConsulting
  433. NeuExcell Therapeutics
  434. Neuracle Genetics
  435. Neuralstem
  436. Neurocore
  437. Neurogene
  438. Neurophth Therapeutics
  439. Nikon CeLL innovation
  440. Ninevah Therapeutics
  441. Nkarta
  442. Noble Life Sciences
  443. Noga Therapeutics
  444. Nohla Therapeutics
  445. Noile-Immune Biotech
  446. Northern Therapeutics
  447. Northwest Biotherapeutics
  448. Novadip Biosciences
  449. Novartis
  450. NovaRx
  451. NovaTrials
  452. Novella Clinical
  453. Novex Innovations
  454. Novotech 
  455. Nuntius Therapeutics
  456. Nuo Therapeutics
  457. Nuventra (Acquired by Allucent)
  458. OBiO Technology
  459. OhioHealth
  460. OiDE BetaRevive
  461. Oisin Biotechnologies
  462. Ology Bioservices
  463. OncoBay Clinical
  464. Oncobiomed
  465. Oncolys BioPharma
  466. Oncorus
  467. OncoSenX
  468. Opexa Therapeutics
  469. Opus Genetics
  470. ORCA Therapeutics
  471. Orchard Therapeutics
  472. Osiris Therapeutics
  473. Oxford BioMedica
  474. Oxular
  475. PathoQuest 
  476. Pattern BioSciences
  477. PDC*line Pharma
  478. PeriphaGen
  479. PersonGen BioTherapeutics
  480. Pfizer
  481. PharmaBio
  482. Pharmahungary 
  483. PharmaLex
  484. Pharmaron 
  485. Pharmaseed
  486. Pharmicell
  487. Phoenix Nest
  488. PhorMed
  489. Pilgrim Quality Solutions
  490. Pinze Lifetechnology
  491. Pique Therapeutics
  492. Pluristem Therapeutics
  493. Plus Therapeutics
  494. Poseida Therapeutics
  495. PPD
  496. PRC Clinical
  497. Precigen
  498. Precision BioSciences
  499. Precision for Medicine
  500. Pregene ShenZhen Biotechnology
  501. Primera Analytical Solutions
  502. Promethera Biosciences
  503. ProPharma
  504. ProtaGene (Formerly known as  Protagen Protein Services)
  505. Provia Laboratories
  506. PSI CRO
  507. PsiOxus Therapeutics
  508. PSNResearch
  509. PTC Therapeutics
  510. Purespring Therapeutics
  511. QbD
  512. QPS
  513. Q-Trials
  514. Quality Assistance
  515. Radyus Research
  516. Redbiotec
  517. Redpin Therapeutics
  518. Reflection Biotechnologies
  519. Regeneris Medical
  520. Regeneron
  521. Regeneus
  522. regenold
  523. REGENXBIO
  524. Rejuvenate Bio
  525. Remedium Bio
  526. ReNeuron
  527. Renova Therapeutics
  528. Research Dynamics
  529. Rexgenero
  530. Reyon Pharmaceutical
  531. RHEACELL
  532. Ring Therapeutics
  533. Riyadh Pharma
  534. Rocket Pharmaceuticals
  535. Roslin Cell Therapies
  536. Rubius Therapeutics
  537. S.Biomedics
  538. Strategic Preclinical Product Development (S2PD)
  539. SalioGen Therapeutics
  540. Sana Biotechnology
  541. Sangamo Therapeutics
  542. Sanofi
  543. Sarah Cannon Development Innovations
  544. Sarepta Therapeutics
  545. Saronic Biotechnology
  546. SBH Sciences
  547. Scancell
  548. Scandinavian CRO
  549. SCiAN Services
  550. Sclnow Biotechnology
  551. SCM Lifescience
  552. Scope International
  553. Seattle Genetics
  554. Selecta Biosciences
  555. Seneca Therapeutics
  556. Sensorion
  557. Sentien Biotechnologies
  558. Sermes CRO
  559. Sernova
  560. Servier
  561. Seven and Eight Biopharmaceuticals
  562. Shanghai BDgene Technology
  563. Shanghai Bioray Laboratory
  564. Shanghai GeneChem
  565. Shanghai Houchao Biotechnology
  566. Shanghai iCELL Biotechnology
  567. Shanghai Longyao Biotechnology
  568. Shanghai Sunway Biotech
  569. Shanghai Unicar-Therapy Bio-medicine Technology
  570. Shenzhen BinDeBio
  571. Shenzhen Hornetcorn Biotechnology
  572. Shionogi
  573. Sibiono GeneTech
  574. SillaJen
  575. Sinclair Research
  576. Sinobioway Cell Therapy
  577. SMS-oncology
  578. SMT Bio
  579. SNBL USA
  580. Solid Biosciences
  581. Sorrento Therapeutics
  582. SOTIO
  583. SparingVision
  584. Spark Therapeutics
  585. Spirovant Sciences
  586. SpliceBio
  587. SQZ Biotechnologies
  588. Stem Cell Arabia
  589. Stemmatters 
  590. StrideBio
  591. STRM.BIO
  592. Sumitomo Dainippon Pharma
  593. Super-T Cell Cancer Company
  594. Surface Oncology
  595. Svar Life Science
  596. SwanBio Therapeutics
  597. Symbion Research International
  598. Syneos Health
  599. Synteract (Acquired by Syneos Health)
  600. Taconic Biosciences
  601. Tactiva Therapeutics
  602. Taiwan Bio Therapeutics
  603. Takara Bio
  604. Takeda Pharmaceutical
  605. Tamid Bio
  606. TapImmune 
  607. Targazyme
  608. Targovax
  609. TC BioPharm
  610. TCR2 Therapeutics
  611. TCTC Group
  612. TeamedOn International
  613. TechnoPharmaSphere
  614. Tella
  615. Tenaya Therapeutics
  616. Tessa Therapeutics
  617. Tetraneuron
  618. TFS
  619. The Cell Factory (A subsidiary of Esperite)
  620. The Discovery Labs Center for Breakthrough Medicines
  621. TheraBiologics
  622. Theradex Oncology
  623. Theravectys
  624. ThermoGenesis
  625. Tianhe Stem Cell Biotechnologies
  626. TiGenix
  627. TILT Biotherapeutics
  628. Tmunity Therapeutics
  629. TNK Therapeutics
  630. ToolGen
  631. TotipotentRX
  632. TRACT Therapeutics
  633. TransCell Science
  634. TransCure BioServices
  635. Transgene
  636. Translational Drug Development 
  637. TreeFrog Therapeutics
  638. TFS HealthScience
  639. Trialbee
  640. Triumvira Immunologics
  641. TVAX Biomedical
  642. Tyris Therapeutics
  643. U.S. Stem Cell
  644. UCB
  645. Ultragenyx Pharmaceutical
  646. uniQure Biopharma
  647. Universal Cells
  648. Urovant Sciences
  649. Vaccinogen
  650. VBL Therapeutics
  651. VCN Biosciences
  652. VectorY Therapeutics
  653. Vericel
  654. Veristat
  655. VetStem Biopharma
  656. ViGeneron
  657. ViroMed
  658. Viscofan BioEngineering
  659. Vivotecnia
  660. Voyager Therapeutics
  661. VREX Therapeutics
  662. Waisman Biomanufacturing
  663. Wake Forest Innovations
  664. WCCT Global
  665. WCG IRB (Formerly known as WIRB)
  666. West Biotherapy
  667. Wissenschaftlicher Service Pharma (WiSP)
  668. Wize Pharma
  669. Worldwide Clinical Trials
  670. Wuhan Binhui Biotechnology
  671. Wuhan Sian Medical Technology
  672. WuXi AppTec
  673. Wyvern Pharmaceuticals
  674. Xalud Therapeutics
  675. Xcell Biosciences
  676. Xcelthera
  677. XEME Biopharma
  678. XyloCor Therapeutics
  679. Zelluna Immunotherapy 
  680. Zimmer Biomet
  681. Ziopharm Oncology

Segmentation

Market Segments Details

Forecast Period

  • 2022 – 2035

Area of Expertise

  • Cell Therapy
  • Gene Therapy

Scale of Operation

  • Clinical
  • Preclinical
  • Discovery

Therapeutic Area

  • Oncological Disorders
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Autoimmune Disorders
  • Blood Disorders
  • Rare / Genetic Disorders
  • Other Disorders

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • MENA
  • Latin America
  • Rest of the World 

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com